CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. (Q46426075)
Jump to navigation
Jump to search
scientific article published on 23 June 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. |
scientific article published on 23 June 2017 |
Statements
1 reference
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. (English)
1 reference
Jatinder K Lamba
1 reference
Lata Chauhan
1 reference
Miyoung Shin
1 reference
Michael R Loken
1 reference
Jessica A Pollard
1 reference
Yi-Cheng Wang
1 reference
Rhonda E Ries
1 reference
Richard Aplenc
1 reference
Betsy A Hirsch
1 reference
Susana C Raimondi
1 reference
Roland B Walter
1 reference
Irwin D Bernstein
1 reference
Alan S Gamis
1 reference
Todd A Alonzo
1 reference
Soheil Meshinchi
1 reference
23 June 2017
1 reference
1 reference
35
1 reference
23
1 reference
2674-2682
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference